A new trading day began on Monday, with Allogene Therapeutics Inc (NASDAQ: ALLO) stock price down -4.24% from the previous day of trading, before settling in for the closing price of $1.18. ALLO’s price has ranged from $0.86 to $3.78 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 6.26% over the past five years. Meanwhile, its annual earnings per share averaged 23.59%. With a float of $149.51 million, this company’s outstanding shares have now reached $218.60 million.
Let’s look at the performance matrix of the company that is accounted for 229 employees. In terms of profitability, gross margin is 100.0%, operating margin of 1222209.09%, and the pretax margin is 1144909.09%.
Allogene Therapeutics Inc (ALLO) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Allogene Therapeutics Inc is 31.65%, while institutional ownership is 66.03%. The most recent insider transaction that took place on Jun 10 ’25, was worth 52,377. In this transaction Director of this company sold 36,885 shares at a rate of $1.42, taking the stock ownership to the 107,431 shares. Before that another transaction happened on Jun 10 ’25, when Company’s Director proposed sale 36,885 for $1.42, making the entire transaction worth $52,391.
Allogene Therapeutics Inc (ALLO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 23.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.47% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Here are Allogene Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.23, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.99 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics Inc (NASDAQ: ALLO) saw its 5-day average volume 2.98 million, a negative change from its year-to-date volume of 4.29 million. As of the previous 9 days, the stock’s Stochastic %D was 9.06%.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 9.18%, which indicates a significant increase from 2.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.16% in the past 14 days, which was lower than the 117.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3087, while its 200-day Moving Average is $1.9623. Nevertheless, the first resistance level for the watch stands at $1.1733 in the near term. At $1.2167, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.2433. If the price goes on to break the first support level at $1.1033, it is likely to go to the next support level at $1.0767. The third support level lies at $1.0333 if the price breaches the second support level.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
With a market capitalization of 247.17 million, the company has a total of 218,731K Shares Outstanding. Currently, annual sales are 20 K while annual income is -257,590 K. The company’s previous quarter sales were 0 K while its latest quarter income was -59,730 K.
